Nafamostat mesilate (NM), a synthetic serine protease inhibitor, has been used increasingly
as an anticoagulant during continuous renal replacement therapy (CRRT). However, there,
are limited data from randomized studies on NM use in patients with a bleeding tendency.
This prospective study evaluated the efficacy and safety of NM use during CRRT in patients
with acute kidney injury (AKI) patients at high risk of bleeding.